Aims: Both amyloid deposition and neuroinflammation appear in the early course of Alzheimer's disease (AD). However, the progression of neuroinflammation and its relationship with amyloid deposition and behavioral changes have not been fully elucidated. A better understanding the role of neuroinflammation in AD might extend our current knowledge to therapeutic intervention possibilities.
| INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disease and is mainly characterized by memory loss. Although the exact mechanisms of AD have not been fully understood, amyloid β protein (Aβ) is believed to be the causative agent of Alzheimer's pathologies. 1 In addition to extracellular Aβ plaques and intracellular neurofibrillary tangles, neuroinflammation also is an early pathological manifestation in AD brains.
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Robust activation of microglia is often in close association with amyloid plaques which are also surrounded by reactive astrocytes. 3, 4 Nevertheless, the diverse physiological functions of glial activation might be a double-edged sword complicating AD pathologies and clinical presentations. Initial glial activation is believed to be one key defensive mechanism of the brain eliminating the toxic Aβ. 5, 6 Yet, this process becomes notably vicious by creating chronic and self-sustaining inflammatory reactions as disease progresses, leading to further neurotoxic damage. 7, 8 Epidemiological studies in human have indicated that increased inflammatory responses increased the risk of developing a sporadic late-onset AD, 9 whereas a long-term suppression of inflammation may reduce risk for AD and possibly delay the onset of the disease. 10, 11 In animal studies, inhibition of proinflammatory signaling of the cytokines interleukin 12 (IL-12) and interleukin 23 in APP/PS1 mice has been shown to reduce glial activation and cognitive decline. 12 All these evidences suggest that neuroinflammation characterized by frank microglial and astroglial activation and subsequent upregulation of proinflammatory mediators might be a crucial event in the pathogenesis of AD.
13
Although it is well documented that neuroinflammatory processes exist in the brains of patients with AD, 14 whether the progression of neuroinflammation is closely related to cognitive decline has not been fully elucidated. As these underlying mechanisms rarely occur in isolation, a better understanding of the exact contribution of neuroinflammation to the cognitive decline along with the undergoing amyloidogenic process in AD may provide benefits for the prevention and treatment of this devastating disease. To clarify the relationships among behavioral changes, amyloid deposition, and neuroinflammation in AD, a double-transgenic mouse model expressing both mutant human amyloid precursor protein (APP) and mutant presenilin 1 (PS1) was employed. Both amyloid pathologies and behavioral impairments in 6-and 9-month-old transgenic mice have been described in our previous study. 15 In this study, we systematically characterized the changes in behavioral abnormalities, brain amyloid pathologies, and neuroinflammation in the APP/PS1 double-transgenic mice with an age range of 2-22 months.
| MATERIAL AND METHODS

| APP/PS1 double-transgenic mice and genotyping
The AD mouse model used is the APP K670N/M671L /PS1 M146L doublemutant mice, and they were generated by crossing single trans- 
| Y-maze test
Spatial short-term working memory in mice was assessed by the Y-maze test as previously described. 18 Briefly, animals were individually placed at the end of one arm and allowed to move freely through the maze during an 8-minute session. Mice tend to explore the maze systematically, entering each arm in turn. The ability to alternate requires mice to know which arm they have already visited.
Spontaneous alternation behavior was defined as entries into all three arms on consecutive choices in overlapping triplet sets. The percent spontaneous alternation behavior was calculated as the ratio of actual to possible alternations (defined as the total number of arm entries minus 2) multiplied by 100.
| Morris water maze test
The spatial learning and memory were evaluated by the Morris water maze. 19 Water maze testing occurred in a circular and galvanized pool (120 cm diameter×50 cm height) with a white interior. The water temperature was kept at 20-23°C. The surface area of the water pool was divided into four equal quadrants with one visual cue for each quadrant. Mice received hidden-platform trials from Day 1 to Day 4 for 4 days, and a probe trial on Day 5. In the hidden-platform (acquisition) trials, the clear platform (10 cm in diameter) was placed in one of the four maze quadrants and submerged 1 cm below the water surface. Mice were required to find the hidden platform using only distal spatial cues available in the behavioral room. A different starting position was used on each trial. They were given 60 seconds (s) to climb onto the hidden platform. If mice could not locate the platform within 60 seconds, they were guided to the platform. On reaching the platform, mice were allowed to remain on it for 10 seconds. In the probe trial, the platform was removed from the water pool and mice were allowed to swim for 60 seconds to assess memory consolidation 24 hours after the last hidden-platform trial. The time spent in the target quadrant and the number of target area (the previous platform location) crossings were analyzed as measures of degree of spatial memory retention.
| Brain tissue processing
At the completion of behavioral testing, animals were anesthetized and perfused with ice-cold 0.01 mol/L phosphate-buffered saline (PBS, pH 7.4). The brains were rapidly removed, immersed in 4% paraformaldehyde, and then cryoprotected in a 30% sucrose/PBS solution. Finally, brains were cut into 30-μm-thick coronal sections using a sliding microtome. 
| Immunohistochemistry
| Immunofluorescence
| Congo red staining
Mouse brain sections were stained with Congo red solution using a commercially available Congo red kit (Sigma-Aldrich, St. Louis, MI, USA) as per the manufacturer's protocol.
| Thioflavin T staining
In addition to Congo red staining, Aβ plaques were also identified by Thioflavin T staining. Brain sections were stained with 1% Thioflavin T solution and then visualized using a fluorescent microscope (Olympus).
| Image analyses
Immunohistochemical slides were viewed with an Axio Imager M2, and the Zen software for image acquisition (Carl Zeiss, Jena, Germany). The plaque number was reported as the total number of plaques counted in frontal cortex and hippocampus after Congo red or Thioflavin T staining. The percentage of the area occupied by 4G8, GFAP, and CD11b in the brain was, respectively, calculated for each age group using Image-Pro Plus software (Media Cybernetics, Silver
Spring, MD, USA). The threshold of detection was kept consistent between each analysis.
| Neural cell counts
Neural cell counts of cortical areas were performed at a magnification of 10× on 30-μm-thick sections stained with NeuN antibody. All counts of sections from the same mouse were averaged to derive the number of neuron per mouse. All counts were performed in a blinded fashion.
| Statistical analysis
All results were expressed as means±standard error of the mean (SEM). Analyses were performed using a one-way or two-way analysis of variance (ANOVA) followed by a Newman-Keuls post hoc test for multiple comparisons. A two-tailed t test for independent samples was used for two-group comparisons. Differences were considered significant at P<.05.
| RESULTS
| Spatial learning and memory deficits in APP/PS1 mice
Spatial short-term working memory was evaluated using a Y-maze test in 3-, 5-, 9-, and 12-month-old mice. At all ages except the 3 months old, APP/PS1 mice exhibited impaired short-term memory as they showed lower percentage of spontaneous alternation than age-matched WT mice, and the deficit seemed greater in older mice, but there was no statistical significance ( Figure 1A ). General locomo- Spatial memory retention was assessed by the time spent in the target quadrant (the platform-located quadrant during the acquisition trials) and the number of target area (the previous platform location)
crossings in the probe test. As shown in Figure 2B , all APP/PS1 mice except the 3-month-old mice spent less time in the target quadrant compared with their age-matched WT mice. However, no significant difference was observed in crossing times ( Figure 2C ).
There was no significant difference between APP/PS1 and their WT littermates in the mean swimming speed in all age groups (P>.05, respectively; data not shown). This indicates that there were no observable motor deficits associated with water maze test and the impaired escaped latency in APP/PS1 mice was not due to motor dysfunctions.
APP/PS1 mice have been reported to exhibit an age-dependent deterioration in the overall performance in a water maze test. 20 Thus, we averaged escape latencies to reach the hidden platform of APP/ PS1 mice in all trials of each day during acquisition and compared them to their age-matched WT mice which were defined as 100%, the differences in the overall performance between APP/PS1 and their counterparts indeed progressively increased up to the age of 9 months but then plateaued at the age of 12 months (P<.0036, Figure 3) Figure 3 ).
| Cerebral Aβ deposition in APP/PS1 mice
Aβ plaque deposits in the cortex and hippocampus of the mice were as- Figure 4B ). 4G8 immunostaining showed increased immunoreactivity of diffuse plaques with advancing age as 4G8 antibody stained both compact and diffuse Aβ.
| Early glial response accompanies amyloid plaques
Serial adjacent sections with the same brain reference position used for Aβ deposition studies were evaluated for activation of microglia and astrocytes using anti-CD11b and anti-GFAP antibodies, respectively.
Although rare and occasional CD11b-positive microglia appeared in 2-month-old APP/PS1 mice, small clustered CD11b-positive microglia were first consistently detected in both cortex and hippocampus of 3-month-old transgenic mice, and the CD11b immunoreactivity was increased in both the number and size of clusters ( Figure 5A , a-f). 
F I G U R E 5
| No apparent neuronal cell loss in APP/PS1 mice
To further investigate the density of neurons in APP/PS1 mice, adjacent sections with the same brain reference position were stained with the general neuronal nuclear marker NeuN. As shown in Figure 7 , the density of NeuN-positive neurons in cortex was nearly indistinguishable between transgenic and age-matched WT mice. These data provided evidence that this APP/PS1 double-transgenic mouse model does not cause any appreciable neuronal cell loss in cortex despite the presence of robust amyloid plaques, suggesting that memory deterioration might not be directly caused by neuronal degeneration.
| DISCUSSION
As Aβ plaques are considered to be the major neuropathological fea- We first screened the spatial learning and memory abilities in 3-, 5-, 9-, and 12-month-old mice. Spatial short-term working memory was impaired in all APP/PS1 transgenic groups except the 3-month-old group. However, the deficits did not get greater with age, suggesting that the spatial working memory decline is not a function of age. Consistently, spatial learning and retention memory were also impaired in three transgenic age groups except the 3-month-old group, as the transgenic mice exhibited longer latencies to reach the platform during acquisition trials and spent less amount of time in target quadrant during the probe trial. However, after averaging out the escape latency of all four age groups of APP/PS1 mice in all trials during acquisition and comparing them with age-matched WT groups, the differences in the overall performance between transgenic mice and WT animals were not exactly progressively exacerbated. It was initially increased from the age of 3-9 months and then plateaued between the age of 9 and 12 months, which again confirmed that the degree of spatial learning deficits was not completely age dependent.
Furthermore, this finding is consistent with some clinical studies reporting that old age has been associated with a slower rate of change in cognitive function. 22, 23 Interestingly, however, earlier animal studies have shown an age-dependent spatial memory deterioration in APP/ PS1 mice using the Morris water maze or T maze. 20, 24 This observed discrepancy among different animal models might be due to differences in mouse genetic backgrounds and transgenes, which also reveals some of the challenges in finding a perfect animal model of AD. 
25,26
Therefore, it is reasonable to argue that Aβ may not be the only player driving the cognitive deficits based on our above observations on the change in behavioral abnormalities and amyloid plaques with age. Although the memory impairments observed in 5-month-old transgenic mice coincide with the dramatic increase in amyloid, the rate of cognitive decline slowed down as animal aged from 9 months onwards, whereas the increase in Aβ plaques is still a function of age. This is not the first time that we have observed this discrepancy that amyloid pathology not correlates well with the degree of cognitive impairments. For example, single APP transgenic mice start to show cognitive impairment well before the appearance of amyloid plaques. 27 Thus, various hypotheses have been suggested to explain this incongruity. There is increasing evidence supporting the important role of neuroinflammation in AD. 2, 13 In the central nerve system (CNS), microglia and astrocytes are the major types of glial cells which greatly outnumber neurons. They possess a number of important structural and physiological functions. 28 Although glial accumulation is one of the earliest pathological manifestations in AD brains, 6 many studies on AD might have underestimated their critical roles. In the present study, clustered microglia were first detected in both cortex and hippocampus of APP/ PS1 mice at 3 months of age, and double staining the brains tissues demonstrated that these activated microglia were closely associated with amyloid plaques, suggesting that microglial activation is an early event in response to Aβ. Coincidently, we also found early astrocyte activation which mainly existed in cortex at the same age in transgenic mice. Activated microglia and astrocytes have been reported to be able to internalize and degrade Aβ, 5, 6 suggesting the early response of microglia and astrocytes may be beneficial in facilitating the clearance of Aβ. However, their capacity of clearing Aβ is believed to be much limited or even reduced as disease progresses. Yet another concern arises from that neuronal loss has been thought to produce the cognitive deficits in AD. 33 To confirm, brain tissues were stained with the general neuronal nuclear marker NeuN.
We found no evidence of any appreciable neuronal cell loss in the layer II of cortex in these APP/PS1 transgenic mice despite the presence of robust amyloid plaques. This finding is further substantiated by previous reports also showing that some transgenic AD mouse models often do not exert clear-cut neuronal cell loss along with the undergoing progressive Aβ accumulation. [34] [35] [36] [37] These evidences suggest the importance of neuronal cell dysfunction rather than the loss of neurons in the pathogenesis of cognitive deficits in AD mice. Besides, astrocytes are involved in the regulation of neuronal activity in the brain as they structurally constitute the "tripartite synapse" with neuronal cells and functionally are involved in the release and uptake of gliotransmitters/neurotransmitters in the synaptic cleft. 38 Therefore, glial activation and their released inflammatory mediators could directly contribute to the neuronal dysfunction in AD, which eventually leads to the cognitive impairments.
In conclusion, the present study demonstrated that glial activation was paralleled well with the pattern of learning deficits rather than amyloid in APP/PS1 mice. These findings provided evidence suggesting that neuroinflammation might directly contribute to the development and progression of cognitive deficits in APP/PS1 mice, which could help develop novel intervention and prevention strategies for AD. Nevertheless, the precise relationship between neuroinflammation and cognitive decline is complex and requires further research to be fully understood.
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